The EU Biotech Act: What Sponsors need to know
- PRONAV
- Jun 15
- 6 min read
In December 2025, the European Commission published its draft EU Biotech Act - the most significant overhaul of Europe's life sciences landscape in a generation. A worldwide biotechnology race is already underway and the winners will lead global biomanufacturing and trade for decades. (1) The proposed EU Biotech Act is Europe's most decisive move yet to stay in that race and to make itself a compelling destination for biotech companies looking to scale internationally. For US-based biotech and biopharma companies, it signals a materially different regulatory and investment environment in Europe and this article sets out what the Act contains, what it means for clinical development strategy, and the steps Sponsors should be taking now.
Why Europe's landscape is shifting
Europe has long offered Sponsors a competitive edge: world-class academic institutions, experienced investigators, deep and varied patient pools, and established regulatory authorities. Biotechnology is among the fastest-growing economic sectors in the EU, yet the EU continues to lag behind the United States and China in translating biotech innovation into commercially viable products and large-scale manufacturing.(2) Regulatory complexity, fragmented implementation across member states, and a chronic shortage of late-stage capital has resulted in the EU steadily losing ground to regions that offer faster study start-up timelines, clearer regulatory pathways, and stronger investment ecosystems for emerging biotech companies.
The EU Biotech Act, proposed in December 2025, is the European Commission's direct response to that innovation drain. It is aimed at strengthening the competitiveness of the health biotechnology and biomanufacturing sector in the EU, by simplifying regulatory processes, promoting innovation, boosting EU-based biomanufacturing with new incentives and support tools, and facilitating access to finance, while maintaining high safety, ethics and sustainability standards.(3) Its ambition is not incremental: it covers the full lifecycle of health biotechnology from research and funding through to manufacturing and market access, with a clear mandate to ensure Europe’s competitiveness long into the future.
"Build a world-leading health biotech industry and transform Europe into a Biotech Powerhouse."
— European Commission, December 2025
The four pillars in the Act: Invent. Make. Approve. Use.
EuropaBio, the voice of Europe's biotech industry, has framed the challenge and the opportunity around four imperatives. (1) They're worth understanding, because they map directly to where the Act creates real commercial openings.
Invent
Europe has been the origin of some of the world's most foundational biotechnological discoveries, yet much of that innovation is reaching commercial maturity outside the EU, with the associated economic value, supply chain investment, and employment following it. The Act establishes a clear imperative to anchor that value within Europe.
Make
Europe has a proven track record in biomanufacturing, with established capacity and expertise across sectors. As other global regions accelerate their pivot towards biomanufacturing for sustainability and competitive advantage, Europe must go beyond maintaining its current position by modernising its manufacturing pathways to secure long-term supply chain resilience.
Approve
Regulatory complexity remains Europe's most significant structural disadvantage in biotechnology, meaning novel biotech products consistently fail to reach market at the speed required to serve patients, healthcare systems, or economies. The Act addresses this directly by streamlining approval processes across member states without compromising safety standards.
Use
Uptake pathways and incentives vary considerably across sectors and EU Member States, meaning the benefits of biotechnology innovation are not evenly distributed. The Act creates the policy framework to ensure that patients, healthcare systems, and economies across all EU Member States can access and benefit from fully integrated biotechnology and biomanufacturing.
What the EU Biotech Act contains
The Biotech Act introduces a broad set of provisions to boost domestic European biotech innovation(4) and translation of discoveries into commercially viable products and large-scale manufacturing. For Sponsors, four provisions carry the most immediate strategic relevance(5):
Accelerated CTR timelines
The Act introduces targeted amendments to the EU Clinical Trials Regulation to significantly reduce authorization timelines. Most competing regions already issue decisions within 60 days - the EU has consistently fallen short of that benchmark (between 75 and 106 days). For Sponsors, faster and more predictable timelines directly influence site selection for multinational trials, encouraging a reassessment of programs previously routed away from European sites based on timing to now be redirected.
Regulatory Sandboxes
The Act introduces the concept of Member-State level regulatory sandboxes, a provision encouraging Sponsors to experiment with novel products, processes and technologies under controlled and supervised frameworks before full market entry. This is particularly relevant for Sponsors with innovative modalities that don't fit neatly into existing EU regulatory categories, providing a safe space for pharmaceutical companies, biotechs, researchers and regulators to collaborate under close supervision before they fully comply with all standard regulatory requirements.(7) Inspired by sandboxes used in fintech, if implemented correctly, the provision should allow for faster innovation, better regulatory learning, reduced uncertainty for developers and improved patient access, leading to more practical and innovation-friendly regulatory frameworks.
Dedicated investment facility
A new EU–EIB (European Investment Bank) investment facility targets the late-stage capital gap that has driven European companies to list in the US and pushed US companies to limit their European ambitions. For Sponsors running Phase II/III programs, this creates new co-investment and partnership structures to explore.
12-month SPC extension
Qualifying biotech and ATMP products with EU-based manufacturing, a distinct mechanism of action, and trials in more than two member states will be eligible for an additional 12 months of supplementary protection. For Sponsors with late-stage or commercial-stage assets, this is a meaningful IP lever.
What this means for clinical development strategy
The EU Biotech Act doesn't operate in isolation. It sits within a cluster of over 20 interconnected legislative initiatives — including the Lifesciences Strategy, Bioeconomy Strategy, Critical Medicines Act, and European Innovations Act — all of which shape how biotech products are developed, financed, and brought to market across Europe.(6)
That complexity is exactly why companies need to engage now, not when the ink is dry. The Sponsors that understand this legislative landscape early and build the right European partnerships and supply chain infrastructure in advance will be far better positioned to navigate that evolving framework than those who wait for full implementation.
What Sponsors should do now
The Act is expected to be formally adopted in 2027, with phased application through 2027–2028. That timeline creates a clear window for proactive Sponsors to build advantage.
Specifically:
Assess your pipeline against the Act's provisions now. Which assets qualify for the SPC extension? Do any programs involve ATMP modalities that could benefit from sandbox frameworks? Build this analysis into your EU regulatory strategy before adoption of the Act. Understanding recognition criteria, timelines, and available support mechanisms now will put you ahead of the queue when formal procedures open
Reassess your European clinical trial strategy. Anticipated reductions in clinical trial authorization timelines and more streamlined procedures are set to make Europe a more competitive location for first-in-human studies, early-phase trials, and innovative study designs. Sponsors should evaluate how this changes the calculus on global development sequencing and where European sites sit in their investment allocation.
Review your European clinical supply chain infrastructure. The 12-month SPC extension for qualifying products requires EU-based manufacturing. For Sponsors with lengthy development timelines who have not mapped their European supply chain and CMO relationships may find themselves unable to meet eligibility criteria upon reaching the point of approval.
Explore regulatory sandbox opportunities. Combination products, borderline products, and programs built on novel or unprecedented technologies may not fit cleanly within existing EU regulatory categories. Member State-level regulatory sandboxes provide a mechanism to gather evidence and engage regulators proactively — reducing the risk of costly delays at the point of market authorization application.
Engage with European biotech clusters. The Act actively promotes cooperation and knowledge-sharing across recognized European biotechnology clusters. Membership or formal collaboration with these networks can provide access to shared infrastructure, technical expertise, and coordination support — reducing the operational burden on individual Sponsors while strengthening their European footprint.
Looking ahead
The EU Biotech Act reflects a genuine and substantial policy commitment to making Europe more competitive for biotech innovation, not a minor regulatory refresh. For US Sponsors, it represents a market that is actively restructuring in ways that should make it more predictable, better capitalized, and more supportive of multinational clinical development.
The window to position ahead of that shift is now. Adoption in 2027 will come faster than it seems, and the Sponsors who understand the framework as it evolves, and have already built the right European infrastructure and partnerships, will have a decisive advantage over those engaging for the first time when the regulations land.
REFERENCES
